The total number of records retrieved from this search are 71. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_133	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_134	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_135	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result25% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_136	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result16% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_137	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_138	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_139	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_140	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result32% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_141	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result3% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_142	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_143	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result30% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_144	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result32% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_145	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result15% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_146	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_147	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result33% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_148	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_149	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_150	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result26% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_151	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result49% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_152	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result98% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_153	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result25% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_154	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_155	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result54% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_156	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result58% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_157	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result28% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_158	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result45% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_159	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_160	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result58% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_161	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result30% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_162	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_163	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 2 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_164	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with tubacin - 5 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_165	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_166	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_167	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁷ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_168	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result9% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_169	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result6% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_170	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁶ MOI	In-vitro result3% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_171	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result15% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_172	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_173	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁵ MOI	In-vitro result5% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_174	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result40% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_175	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result44% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_176	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻⁴ MOI	In-vitro result43% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_177	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result49% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_178	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result46% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_179	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻³ MOI	In-vitro result42% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_180	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_181	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_182	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻² MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_183	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_184	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_185	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3⁻¹ MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_186	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result51% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_187	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_188	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration1 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_189	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result54% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_190	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 1 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result52% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_191	Virus nameHerpes simplex virus	Virus strainrQNestin34.5	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CI994 - 3 micromolar starting at 14 hours before infection	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma astrocytoma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayLDH cytotoxicity assay	In-vitro virus concentration3 MOI	In-vitro result60% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26524593
IDOV_2254	Virus nameHerpes simplex virus	Virus strainEquine Herpesvirus type-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22205738
IDOV_2259	Virus nameHerpes simplex virus	Virus strainEquine Herpesvirus type-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration3 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22205738
IDOV_2264	Virus nameHerpes simplex virus	Virus strainEquine Herpesvirus type-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22205738
IDOV_3502	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3503	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result82% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3504	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result78% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3505	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3506	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result18% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3512	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result92% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3513	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result62% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_3514	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of science	Origin of cell lineHuman neuroglioma cell line	Cell lineU251	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result35% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by Propidium iodide method and annexin V-FITC staining	Immunogenic effectNA	Clinical trialNA	PMID28672936
IDOV_4285	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSICB	Origin of cell lineHuman glioblastoma	Cell lineU251	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result34.7 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347